Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Thoracic 1Other solid neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 7Nivolumab 2Ipilimumab 2Cyclophosphamide 2Cisplatin 2spartalizumab 1regorafenib 1rebastinib 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1aldesleukin 1abemaciclib 1Tomography, Optical Coherence 1Talc 1Tablets 1Sirolimus 1Radiofrequency Ablation 1Pemetrexed 1Paclitaxel 1Mitomycin 1Midazolam 1Levoleucovorin 1Leucovorin 1Letrozole 1LY3023414 1Interleukin-2 1Injections 1Immunologic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × LY3023414 × Other solid neoplasm × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡